Velarion · Company Intelligence
Compensation Brief
Fiscal year 2025 · Filings through 2026-06-05

Precision Biosciences (DTIL)

Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$2,189,467
Michael Amoroso total, FY2025
1st
CEO pay percentile vs peers
CEO-to-median pay ratio
96.83%
Say-on-pay support, latest vote
Companies that benchmark against DTIL
5 companies name DTIL as a compensation peer

Each company listed discloses DTIL in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named DTIL in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

01

Summary Compensation Table — fiscal year 2025

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Michael Amoroso$650,875$451,294$1,025,086$0$0$0$62,212$2,189,467
President, Chief Executive Officer and Director
Alex Kelly472,525222,220417,06000022,3111,134,116
Chief Financial Officer
Dario Scimeca445,875193,558252,00000020,208911,641
General Counsel and Secretary

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY20242025
Michael Amoroso$2,189,467
Alex Kelly1,134,116
Dario Scimeca911,641

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Geno GermanoDirector2026-05-20A21,000CommonForm 4 ↗
Kevin J. BuehlerDirector2026-05-20D21,00000Derivative, Class A CommonForm 4 ↗
Melinda BrownDirector2026-05-20D21,00000Derivative, Class A CommonForm 4 ↗
Geno GermanoDirector2026-05-20D21,00000Derivative, Class A CommonForm 4 ↗
Shari Lisa PireDirector2026-05-20A21,000CommonForm 4 ↗
Kevin J. BuehlerDirector2026-05-20A21,000CommonForm 4 ↗
Stanley FrankelDirector2026-05-20A21,000CommonForm 4 ↗
Stanley FrankelDirector2026-05-20D21,00000Derivative, Class A CommonForm 4 ↗
Melinda BrownDirector2026-05-20A21,000CommonForm 4 ↗
Shari Lisa PireDirector2026-05-20D21,00000Derivative, Class A CommonForm 4 ↗
Michael AmorosoDirector2026-06-01A573,88800Derivative, Class A CommonForm 4 ↗
Alex KellyChief Financial Officer2026-06-01A193,68800Derivative, Class A CommonForm 4 ↗
Dario ScimecaGeneral Counsel and Secretary2026-06-01A107,60400Derivative, Class A CommonForm 4 ↗
J. Jefferson SmithChief Research Officer2026-06-01A57,38900Derivative, Class A CommonForm 4 ↗
Kevin J. BuehlerDirector2026-06-03A20,97900Derivative, Class A CommonForm 4 ↗
Shari Lisa PireDirector2026-06-03A20,97900Derivative, Class A CommonForm 4 ↗
Stanley FrankelDirector2026-06-03A20,97900Derivative, Class A CommonForm 4 ↗
Melinda BrownDirector2026-06-03A20,97900Derivative, Class A CommonForm 4 ↗
Geno GermanoDirector2026-06-03A20,97900Derivative, Class A CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

03

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Michael AmorosoRSU$1,025,086
Alex KellyRSU417,060
Dario ScimecaRSU252,000
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Michael Amoroso$1,025,086$0$00.0%
Alex Kelly417,060000.0%
Dario Scimeca252,000000.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Dario ScimecaRSU50,000$208,000
Alex KellyRSU82,750344,240
Dario ScimecaRSU16,85070,096
Michael AmorosoRSU138,842577,583
Dario ScimecaRSU29,815124,030
Alex KellyRSU53,150221,104
Michael AmorosoOption2,08341.4
Alex KellyRSU27,801115,652
Alex KellyRSU3,88816,174
Michael AmorosoRSU203,390846,102
Michael AmorosoRSU74,138308,414
Michael AmorosoRSU8,88836,974
Dario ScimecaRSU1,9788,228
05

Incentive-plan design — the Compensation Discussion & Analysis

We believe that equity awards provide our executives with a strong link to our long-term performance, create an ownership culture and help to align the interests of our executives and our stockholders.

CEO STI target (% of salary)60%
CEO LTI target (% of salary)
Independent consultantAon
Clawback policyTrue
Anti-hedgingTrue
Anti-pledgingTrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-05-2118,696,193612,83618,50496.83%Passed
20252025-05-283,389,745261,406102,18992.84%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20262026-05-2196.83%a
20252025-05-2892.84%b

a. Approved under the standard stated in the filing — “(3) Abstentions are not counted as "votes cast" and thus will have no effect on the approval of this proposal.”.

b. Approved under the standard stated in the filing — “(3) Abstentions are not counted as "votes cast" and thus will have no effect on the approval of this proposal.”.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)
CEO total compensation
Median employee compensation
08

Director compensation — fiscal year 2025

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Stanley R. Frankel, M.DNot independent · Science and Technology (Chair)$52,250$108,150$0$0$173,800$334,200
Kevin J. BuehlerIndependent · Board Chair · Lead Independent Director · Audit · Nominating/Governance84,500108,15000192,650
Geno GermanoIndependent · Audit · Compensation (Chair) · Science and Technology65,750108,15000173,900
Melinda BrownIndependent · Audit (Chair) · Compensation55,000108,15000163,150
Shari Lisa PirIndependent · Compensation · Nominating/Governance (Chair)54,250108,15000162,400
Michael AmorosoEmployee director00000
09

Board fee structure and ownership guideline

Annual cash retainer$40,000
Annual equity retainer
Per board meeting fee
Committee chair fees (audit / comp / nom-gov)7,500 / 6,250 / 3,750
Stock ownership guideline
09b

Total cost of the board

ComponentFY2025
Cash retainers and fees$311,750
Equity awards (grant-date value)$540,750
All other compensation$173,800
Total cost of the board$1,026,300

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies Precision Biosciences names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Precision Biosciences.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Verve Therapeutics, Inc.2024Sekar Kathiresan$639,231$1,683,000$4,727,372$378,972$7,442,663
2Intellia Therapeutics, Inc.2025John Leonard708,0002,443,9201,356,32005,063,899
3Prime Medicine, Inc.2025Allan Reine606,21202,828,798402,0003,894,187
4Editas Medicine, Inc.2025Gilmore O'Neill686,57401,282,937375,1642,353,655
5Precision Biosciences2025Michael Amoroso650,8751,025,086002,189,467
Sangamo Therapeutics, Inc.not in coverage universe

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Precision Biosciences115%RSU 100not disclosedAon
Editas Medicine, Inc.91%Options 100not disclosedPearl Meyer & Partners, LLC
Intellia Therapeutics, Inc.115%Options 40 · RSU 40 · PSU 20Yes — TSR relative to the Nasdaq Biotechnology IndexAlpine Rewards, LLC
Prime Medicine, Inc.120%Options 100not disclosedAlpine Rewards
Sangamo Therapeutics, Inc.not disclosednot disclosednot disclosednot disclosed
Verve Therapeutics, Inc.not disclosednot disclosednot disclosedRadford Data & Analytics from Aon plc

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, Michael AmorosoDEF 14A2026-04-080001140361-26-013757Section “Summary Compensation Table” · page 39. As printed: 2,189,467. Filing ↗machine: r2 · c19 · span 829996–830005
2Section 01, Alex KellyDEF 14A2026-04-080001140361-26-013757Section “Summary Compensation Table” · page 39. As printed: 1,134,116. Filing ↗machine: r4 · c19 · span 837788–837797
3Section 01, Dario ScimecaDEF 14A2026-04-080001140361-26-013757Section “Summary Compensation Table” · page 39. As printed: 911,641. Filing ↗machine: r6 · c19 · span 844622–844629
4Section 03, Michael Amoroso RSUDEF 14A2026-04-080001140361-26-013757Section “FUNCTION-DMD” · grants of plan-based awards table. Filing ↗machine: t230 · r2 · c13 · span 828801–828810
5Section 03, Alex Kelly RSUDEF 14A2026-04-080001140361-26-013757Section “FUNCTION-DMD” · grants of plan-based awards table. Filing ↗machine: t230 · r4 · c13 · span 836584–836591
6Section 03, Dario Scimeca RSUDEF 14A2026-04-080001140361-26-013757Section “FUNCTION-DMD” · grants of plan-based awards table. Filing ↗machine: t230 · r6 · c13 · span 843668–843675
7Section 07, pay ratio10-K2026-03-120001628280-26-017019Section “CEO Pay Ratio”. As printed: —. Filing ↗
8Section 08, Stanley R. Frankel, M.DDEF 14A2026-04-080001140361-26-013757Section “Director Compensation”. As printed: 334,200. Filing ↗machine: r4 · c13 · span 1008578–1008585
9Section 08, Kevin J. BuehlerDEF 14A2026-04-080001140361-26-013757Section “Director Compensation”. As printed: 192,650. Filing ↗machine: t262 · r3 · c13 · span 1005719–1005726
10Section 08, Geno GermanoDEF 14A2026-04-080001140361-26-013757Section “Director Compensation”. As printed: 173,900. Filing ↗machine: t262 · r5 · c13 · span 1011449–1011456
11Section 08, Melinda BrownDEF 14A2026-04-080001140361-26-013757Section “Director Compensation”. As printed: 163,150. Filing ↗machine: t262 · r2 · c13 · span 1002844–1002851
12Section 08, Shari Lisa PirDEF 14A2026-04-080001140361-26-013757Section “Director Compensation”. As printed: 162,400. Filing ↗
13Section 08, Michael AmorosoDEF 14A2026-04-080001140361-26-013757Section “Director Compensation”. As printed: 0. Filing ↗
14Section 02, Geno Germano 2026-05-20Form 42026-05-220001628280-26-037533Insider equity transaction reported since the proxy statement. Filing ↗
15Section 02, Kevin J. Buehler 2026-05-20Form 42026-05-220001628280-26-037539Insider equity transaction reported since the proxy statement. Filing ↗
16Section 02, Melinda Brown 2026-05-20Form 42026-05-220001628280-26-037536Insider equity transaction reported since the proxy statement. Filing ↗
17Section 02, Geno Germano 2026-05-20Form 42026-05-220001628280-26-037533Insider equity transaction reported since the proxy statement. Filing ↗
18Section 02, Shari Lisa Pire 2026-05-20Form 42026-05-220001628280-26-037534Insider equity transaction reported since the proxy statement. Filing ↗
19Section 02, Kevin J. Buehler 2026-05-20Form 42026-05-220001628280-26-037539Insider equity transaction reported since the proxy statement. Filing ↗
20Section 02, Stanley Frankel 2026-05-20Form 42026-05-220001628280-26-037537Insider equity transaction reported since the proxy statement. Filing ↗
21Section 02, Stanley Frankel 2026-05-20Form 42026-05-220001628280-26-037537Insider equity transaction reported since the proxy statement. Filing ↗
22Section 02, Melinda Brown 2026-05-20Form 42026-05-220001628280-26-037536Insider equity transaction reported since the proxy statement. Filing ↗
23Section 02, Shari Lisa Pire 2026-05-20Form 42026-05-220001628280-26-037534Insider equity transaction reported since the proxy statement. Filing ↗
24Section 02, Michael Amoroso 2026-06-01Form 42026-06-030001628280-26-040212Insider equity transaction reported since the proxy statement. Filing ↗
25Section 02, Alex Kelly 2026-06-01Form 42026-06-030001628280-26-040215Insider equity transaction reported since the proxy statement. Filing ↗
26Section 02, Dario Scimeca 2026-06-01Form 42026-06-030001628280-26-040220Insider equity transaction reported since the proxy statement. Filing ↗
27Section 02, J. Jefferson Smith 2026-06-01Form 42026-06-030001628280-26-040223Insider equity transaction reported since the proxy statement. Filing ↗
28Section 02, Kevin J. Buehler 2026-06-03Form 42026-06-050001628280-26-041037Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, Shari Lisa Pire 2026-06-03Form 42026-06-050001628280-26-041039Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, Stanley Frankel 2026-06-03Form 42026-06-050001628280-26-041043Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Melinda Brown 2026-06-03Form 42026-06-050001628280-26-041045Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, Geno Germano 2026-06-03Form 42026-06-050001628280-26-041041Insider equity transaction reported since the proxy statement. Filing ↗
33Section 06, 2026 voteForm 8-K2026-05-260001628280-26-038220Item 5.07 · say-on-pay result. As reported: 96.83% (votes for as printed: 18,696,193). Filing ↗
34Section 06, 2025 voteForm 8-K2025-06-030000950170-25-080564Item 5.07 · say-on-pay result. As reported: 92.84% (votes for as printed: 3,389,745). Filing ↗
35Section 03b vehicle mix (computed)ComputedcomputedRSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
36Section 09b board cost (computed)ComputedcomputedCash 311,750 + equity 540,750 + all other 173,800 = 1,026,300, summed across the director compensation table rows.machine: formula: Σ = 1,026,300
37Verve Therapeutics, Inc., Section 10b CEO totalDEF 14A2025-04-250000950170-25-058325CEO total compensation as printed in Verve Therapeutics, Inc.'s own proxy. As printed: 7,442,663. Filing ↗machine: r2 · c20 · span 327433–327442
38Intellia Therapeutics, Inc., Section 10b CEO totalDEF 14A2026-04-300001193125-26-197283CEO total compensation as printed in Intellia Therapeutics, Inc.'s own proxy. As printed: 5,063,899. Filing ↗machine: r2 · c25 · span 749290–749299
39Prime Medicine, Inc., Section 10b CEO totalDEF 14A2026-04-230001628280-26-026697CEO total compensation as printed in Prime Medicine, Inc.'s own proxy. As printed: 3,894,187. Filing ↗machine: r2 · c42 · span 285179–285188
40Editas Medicine, Inc., Section 10b CEO totalDEF 14A2026-04-280001650664-26-000037CEO total compensation as printed in Editas Medicine, Inc.'s own proxy. As printed: 2,353,655. Filing ↗machine: t42 · r2 · c12 · span 545455–545464
41Precision Biosciences (subject), Section 10b CEO totalDEF 14A2026-04-080001140361-26-013757CEO total compensation as printed in Precision Biosciences's own proxy. As printed: 2,189,467. Filing ↗machine: r2 · c19 · span 829996–830005
42Section 10a, Editas Medicine, Inc. reciprocityDEF 14A0001650664-26-000037Editas Medicine, Inc.'s most recent proxy was read; its disclosed peer group does not include Precision Biosciences. Filing ↗
43Section 10a, Intellia Therapeutics, Inc. reciprocityDEF 14A0001193125-26-197283Intellia Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Precision Biosciences. Filing ↗